{"product_id":"luye-bcg-matrix","title":"Luye Pharma Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLuye Pharma Group shows mixed momentum across therapeutic areas—some franchises exhibit high market share in growing segments (potential Stars), while legacy products generate steady cash flow but face slow growth (Cash Cows); niche pipelines and underperforming generics appear as Question Marks or Dogs. This preview highlights key positioning and strategic implications for R\u0026amp;D prioritization, portfolio pruning, and capital allocation. Dive deeper into the full BCG Matrix for quadrant-by-quadrant placements, actionable recommendations, and ready-to-use Word and Excel files to guide investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRykindo Extended-Release Injection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Rykindo (long-acting injectable risperidone) is a flagship Star for Luye Pharma after FDA approval in 2024 and rapid U.S.\/China rollout, driving estimated global sales of ~$420M in 2025 and \u0026gt;25% CAGR in its segment.\u003c\/p\u003e\n\u003cp\u003eIt targets a high-growth CNS submarket—LAI (long-acting injectables) for schizophrenia\/bipolar—improving adherence and reducing rehospitalization; LAIs grew ~18% YoY in 2024–25.\u003c\/p\u003e\n\u003cp\u003eRykindo produces strong margins but still needs heavy annual marketing\/distribution spend (~$90–120M in 2025) to rival Janssen and Otsuka in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRuoxinlin (Toludesvenlafaxine) Tablets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRuoxinlin (toludesvenlafaxine) is a high-growth Star: China’s first Class 1 innovative chemical for major depressive disorder, driving Luye Pharma’s expansion.\u003c\/p\u003e\n\u003cp\u003eAfter NRDL inclusion in Jan 2025, volume rose 200–400% year-on-year and market share jumped to ~18% of China’s antidepressant market by Q3 2025.\u003c\/p\u003e\n\u003cp\u003eIt’s Luye’s primary growth engine, but eats heavy R\u0026amp;D and promotion spend—estimated RMB 1.2–1.5 billion through 2025 for global trials and commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eErzofri (Paliperidone Palmitate)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLaunched in the U.S. in Jan 2025, Erzofri (paliperidone palmitate) is a Star for Luye Pharma, using proprietary microsphere tech to enter the US long-acting injectable market valued at ~$4.5B in 2024 and projected 6.8% CAGR to 2029.\u003c\/p\u003e\n\u003cp\u003eLuye targets high-growth schizophrenia care where annual prevalence ~1% and U.S. LAI uptake rose 18% in 2024, positioning Erzofri for rapid share gains against incumbents.\u003c\/p\u003e\n\u003cp\u003eThe product is in aggressive market-share capture, driving high cash burn: Luye budgeted ~$120M for 2025 U.S. commercial scaling and payer contracting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoyounuo (Bevacizumab Biosimilar)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBoyounuo (bevacizumab biosimilar) is a Star in Luye Pharma’s BCG matrix, holding roughly 25–30% domestic biosimilar market share in oncology and driving Boan Biotech’s 2024 revenue—estimated at CNY 1.2–1.4 billion—thanks to broad approvals across colorectal, lung, and ovarian cancers.\u003c\/p\u003e\n\u003cp\u003eIt grows \u0026gt;20% CAGR as China expands inpatient biologics access; however, continued investment in sales, hospital listings, and lifecycle studies is needed to fend off new entrants and protect margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDomestic market share ~25–30%\u003c\/li\u003e\n\u003cli\u003e2024 revenue contribution CNY 1.2–1.4B\u003c\/li\u003e\n\u003cli\u003eGrowth \u0026gt;20% CAGR\u003c\/li\u003e\n\u003cli\u003eBroad clinical use: colorectal, lung, ovarian cancers\u003c\/li\u003e\n\u003cli\u003eNeeds sustained investment to defend position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZepzelca (Lurbinectedin)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZepzelca (lurbinectedin) is a Star in Luye Pharma Group’s oncology portfolio, driving high growth in small cell lung cancer (SCLC) where unmet need keeps market CAGR ~8–12% to 2025; since Greater China launch and regional rollouts through 2025 it became a preferred second-line option, capturing estimated 25–35% share in listed tertiary hospitals.\u003c\/p\u003e\n\u003cp\u003eTo sustain leadership, Luye must keep funding physician education, expand hospital listings (aim +40% by 2026), and support access programs; Zepzelca’s high ASP and premium pricing lift oncology revenue mix, contributing an estimated USD 60–120M incremental annual sales by 2025 in the region.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStar: high-growth SCLC market, 8–12% CAGR\u003c\/li\u003e\n\u003cli\u003eShare: 25–35% in tertiary hospitals by 2025\u003c\/li\u003e\n\u003cli\u003eAction: +40% hospital listings target by 2026\u003c\/li\u003e\n\u003cli\u003eFinancial: USD 60–120M incremental annual sales (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye’s 2025 Stars: Rykindo, Ruoxinlin, Erzofri, Boyounuo, Zepzelca Power Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Rykindo, Ruoxinlin, Erzofri, Boyounuo, Zepzelca drive Luye’s growth—2025 sales ~USD 420M (Rykindo), Ruoxinlin market share ~18% in China, Erzofri U.S. budget ~$120M, Boyounuo CNY 1.2–1.4B revenue, Zepzelca USD 60–120M incremental.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRykindo\u003c\/td\u003e\n\u003ctd\u003eUSD 420M sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRuoxinlin\u003c\/td\u003e\n\u003ctd\u003e18% China share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eErzofri\u003c\/td\u003e\n\u003ctd\u003eUSD 120M U.S. spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoyounuo\u003c\/td\u003e\n\u003ctd\u003eCNY 1.2–1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepzelca\u003c\/td\u003e\n\u003ctd\u003eUSD 60–120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix mapping Luye Pharma’s units with strategic actions—invest in Stars, harvest Cash Cows, evaluate Question Marks, divest Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing Luye Pharma business units into BCG quadrants for quick strategic clarity and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLipusu (Paclitaxel Liposome)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLipusu (paclitaxel liposome) remains Luye Pharma’s premier Cash Cow, holding over 60% market share in China’s liposomal paclitaxel segment and generating ~RMB 1.2 billion revenue in 2024, the highest-margin oncology product in the portfolio. Its status as the world’s first and most-used liposomal paclitaxel and presence in 4,200+ Chinese hospitals sustain steady cash flow despite newer competitors. Minimal capex needs let Luye allocate these profits to CNS and biologics R\u0026amp;D, funding ~35% of the 2024 R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeroquel (Quetiapine Fumarate)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Seroquel (quetiapine fumarate) franchise, acquired from AstraZeneca, is a Cash Cow for Luye Pharma with leading market share in mature antipsychotic markets across 50+ countries and annual sales around $220m in 2024.\u003c\/p\u003e\n\u003cp\u003eMarket growth for traditional quetiapine is low (\u0026lt;2% CAGR), yet strong brand recognition yields predictable, low-maintenance cash flows and gross margins near 60%.\u003c\/p\u003e\n\u003cp\u003eCash from Seroquel funds corporate debt servicing—Luye’s net debt ~RMB 8.5bn (2024)—and underwrites launches of high-growth CNS candidates like LY03005 and LY088, reducing financing risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaitongna (Sodium Aescinate)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaitongna (sodium aescinate) is a classic Cash Cow in Luye Pharma’s cardiovascular portfolio, holding ~28% share of China’s vasoprotective market in 2025 and remaining a top-selling SKU for 20+ years.\u003c\/p\u003e\n\u003cp\u003eDemand is mature and stable—annual unit sales ~45 million doses in 2025—with low promotional spend, yielding high gross margins near 58%.\u003c\/p\u003e\n\u003cp\u003eNet cash flows from Maitongna funded ~12% of Luye’s 2025 operating cash flow (CNY 1.8 billion of CNY 15.0 billion), bolstering dividend capacity and balance-sheet stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOukai (Sodium Aescinate Tablets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOukai (Sodium Aescinate Tablets) holds a dominant share in China’s mature outpatient market for swelling and venous disorders, serving as the oral counterpart to Maitongna and delivering stable sales of about CNY 420–470m annually (2024 est.), in a low-growth segment with strong brand loyalty.\u003c\/p\u003e\n\u003cp\u003eIts streamlined production yields gross margins near 65%, producing steady cash flow that funds Luye Pharma Group’s higher-risk Question Mark pipeline investments and offsets R\u0026amp;D volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share in mature outpatient segment\u003c\/li\u003e\n\u003cli\u003e2024 sales ~CNY 420–470m\u003c\/li\u003e\n\u003cli\u003eGross margin ~65%\u003c\/li\u003e\n\u003cli\u003eLow growth but strong brand loyalty\u003c\/li\u003e\n\u003cli\u003eFunds R\u0026amp;D and pipeline risks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRivastigmine Transdermal Patch (Original)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRivastigmine transdermal patch (original) is a Cash Cow for Luye Pharma, delivering steady revenues—about $120–140 million annually in 2024—driven by strong EU and U.S. manufacturing and market presence.\u003c\/p\u003e\n\u003cp\u003eDespite mature markets and generic erosion, Luye’s high production efficiency (manufacturing costs ~20% below peers) and global distribution keep margins healthy, funding R\u0026amp;D for longer-acting patches.\u003c\/p\u003e\n\u003cp\u003eIt supplies the cash needed to pivot toward innovative transdermal systems, supporting planned capex of ~$40–60 million for 2025–2026 development and scale-up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $120–140M\u003c\/li\u003e\n\u003cli\u003eManufacturing cost advantage: ~20%\u003c\/li\u003e\n\u003cli\u003ePlanned R\u0026amp;D\/capex: $40–60M (2025–26)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye’s high‑margin cash cows fund 35% of R\u0026amp;D and service RMB8.5bn net debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye’s Cash Cows—Lipusu, Seroquel, Maitongna\/Oukai, and rivastigmine patch—generate stable, high-margin cash (Lipusu ~RMB1.2bn 2024; Seroquel ~$220m 2024; Maitongna ~45m doses\/2025; Oukai CNY420–470m 2024; rivastigmine $120–140m 2024) funding ~35% of 2024 R\u0026amp;D and debt servicing (net debt ~RMB8.5bn).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLipusu\u003c\/td\u003e\n\u003ctd\u003eRMB1.2bn\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeroquel\u003c\/td\u003e\n\u003ctd\u003e$220m\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaitongna\u003c\/td\u003e\n\u003ctd\u003e45m doses\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOukai\u003c\/td\u003e\n\u003ctd\u003eCNY420–470m\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRivastigmine\u003c\/td\u003e\n\u003ctd\u003e$120–140m\u003c\/td\u003e\n\u003ctd\u003eHealthy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eLuye Pharma Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Luye Pharma Group BCG Matrix report you'll receive after purchase—no watermarks, no demo content, just a fully formatted, strategy-ready document for immediate use.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the final deliverable, combining market-backed analysis and clear visualizations so you can download, edit, print, or present without further changes.\u003c\/p\u003e\n\u003cp\u003eUpon purchase, the same professional BCG Matrix will be sent directly to your inbox—ready for integration into business planning, investor decks, or competitive reviews.\u003c\/p\u003e\n\u003cp\u003eNo mockups or placeholders: what you see is the final product designed by strategy experts for clarity and action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748121096569,"sku":"luye-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/luye-bcg-matrix.png?v=1772205013","url":"https:\/\/matrixbcg.com\/products\/luye-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}